Mitochondria-Enriched Stem Cells for CNS Disease Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of effective treatments for central nervous system (CNS) diseases and disorders, particularly those unrelated to primary mitochondrial diseases, and existing mitochondrial therapies have not shown significant breakthrough results.

Innovation Solution

Administering human stem cells enriched with healthy and functional mitochondria to patients suffering from CNS-related diseases to increase mitochondrial activity and improve brain function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mitochondrial therapy is administered to treat CNS diseases, then mitochondrial function is improved, but treatment efficacy for non-mitochondrial CNS diseases remains insufficient

Engineering Contradiction:

Improvetreatment efficacyVSAvoidapplicability to different disease types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the key parameter from simply administering mitochondria to administering stem cells that have been pre-enriched with mitochondria. This parameter change (from direct mitochondrial administration to stem cell-mediated mitochondrial delivery) enables the therapy to address both mitochondrial and non-mitochondrial CNS diseases, resolving the contradiction between treatment efficacy and disease type applicability

Inventive Principle:

Principle #35Parameter changes

2Reliability

If stem cells are administered to deliver mitochondria, then mitochondrial activity in CNS is enhanced, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improvemitochondrial function enhancementVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-enriching stem cells with functional mitochondria ex vivo before administration to the patient. This preliminary enrichment step ensures that the stem cells carry sufficient mitochondrial content to effectively treat CNS diseases, while the subsequent single-dose administration simplifies the overall treatment protocol compared to repeated mitochondrial infusions

Inventive Principle:

Principle #10Preliminary action

3Loss of time

If a single round of treatment is used, then treatment time is reduced, but long-term therapeutic effect may be insufficient

Engineering Contradiction:

Improvetreatment durationVSAvoidlong-term therapeutic effect

Core Design Contradiction:

Loss of timeVSDuration of action of stationary object

Solution Approach 1:

The patent employs self-service by utilizing the inherent self-renewal and differentiation capabilities of stem cells. The administered stem cells not only deliver mitochondria but also continue to proliferate and differentiate into functional CNS cells long-term, providing sustained therapeutic effect from a single treatment round without requiring repeated administrations

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS12440515B2Mitochondrial augmentation therapy of brain diseases

Publication Date: 2025.10.14 MINOVIA THERAPEUTICS

AI summary

The present invention provides stem cells enriched with healthy functional mitochondria, pharmaceutical compositions comprising these cells and methods of use thereof for treating brain diseases, disorders and symptoms thereof where the disease may or may not be associated with acquired mitochondrial dysfunction.